UAEM - Licensing and patenting practices of COVID-19 technologies

Sarai Keestra made this Freedom of Information request to University of Nottingham

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was successful.

Dear University of Nottingham,

For the purpose of clarity, please adhere to the following definitions when answering these questions:

Low and middle income country: A country that is defined as ‘low’, ‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year 2018. Income status defined by GNI per capita.
Source: World bank, available online [https://tinyurl.com/y5dwc2qv]

A patent grants an inventor the exclusive rights to his or her invention. A patent holder can stop other people from selling, manufacturing, producing, or using the invention for a certain period of time.
Source: Upcouncil, available online [https://www.upcounsel.com/what-is-a-pate...

Licence: Permission for the licensee to use the intellectual property rights
Source: TaylorWessing, available online [https://www.taylorwessing.com/download/a...

Exclusive Licence: A licence that allows only the named licensee to exploit the relevant IP rights, the licensor is also excluded from exploiting these IP rights.
Non-Exclusive Licence: A licence that grants any number of licensees to exploit the IP.
Source: TaylorWessing, available online [https://www.taylorwessing.com/synapse/co...

Health Technology: ‘Health technology as defined by the WHO: “A health technology is the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives.’
Source: WHO, available online [https://www.who.int/health-technology-as...

START FOI request:
Q1. Can you release your internal strategy regarding licensing and patenting of COVID-19 related health technologies?

Q2. Does the institution have a formal policy on licensing and patenting of COVID-19 related technologies? If yes, please provide a link or PDF to the relevant policy document.

Q3. Has the university considered updating their strategy regarding the licensing and patenting of health technologies since the start of the pandemic?

Q4. Please provide an Excel spreadsheet with headings as displayed below with all the COVID-19 related health technologies LICENSED by the university AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.
Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Q5. Please provide a list of patents granted to your organization for any COVID-19 related health technologies listed by patent family, indicating countries/regions in which the patent has been granted.

Q6. Does the institution have any plans on signing up to the Open-COVID pledge (https://opencovidpledge.org/) or any similar initiative that seeks to minimise intellectual property rights barriers during the COVID-19 pandemic? If yes, please specify.

Q7. Is the institution considering the licensing of COVID-19 related health technologies to the Covid Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP) during the pandemic? If yes, please specify.

END FOI request.
If you have any questions please do not hesitate to contact me by email.

Yours faithfully,

Sarai Keestra

Br-Freedom-Of-Information, University of Nottingham

Dear Sarai

Thank you for your request for information regarding licensing and patenting practices of Covid-19 related health technologies. Your request was received on 26 October 2020 and is being dealt with under the terms of the Freedom of Information Act 2000. The reference number of your request is 4033.

We will aim to respond to your request within twenty working days. Please note this is calculated from the following working day from receipt of your request.

Please be aware that due to the Covid-19 pandemic, and following Government advice, the University is moving to online teaching and staff are working remotely, this may mean that access to some information held locally or on certain systems may not be readily available at this time.

Where it becomes clear that the information you have requested is not available due to the current situation, we will of course write to you and advise you of this.

I hope that this is of help. Please do not hesitate to contact me if you have any enquiries regarding this email.

Yours sincerely,
Karen Page

Information Compliance Officer – Freedom of Information
Registrar’s Department

Web: www.nottingham.ac.uk/freedom-of-informat...
Email: [University of Nottingham request email]

show quoted sections

Br-Freedom-Of-Information, University of Nottingham

1 Attachment

Dear Sarai

I am writing further to your request for information regarding licensing and patenting practices of Covid-19 related health technologies. A search of our electronic and paper records has been completed.

In answer to your request:

Q1. Can you release your internal strategy regarding licensing and patenting of COVID-19 related health technologies?

We do not currently have a specific strategy on licensing and patenting COVID-19 related health technologies.

Q2. Does the institution have a formal policy on licensing and patenting of COVID-19 related technologies? If yes, please provide a link or PDF to the relevant policy document.

We do not currently have a specific policy on licensing and patenting COVID-19 related health technologies.

Q3. Has the university considered updating their strategy regarding the licensing and patenting of health technologies since the start of the pandemic?

Not at this time.

Q4. Please provide an Excel spreadsheet with headings as displayed below with all the COVID-19 related health technologies LICENSED by the university AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.

Nil return.

Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Q5. Please provide a list of patents granted to your organization for any COVID-19 related health technologies listed by patent family, indicating countries/regions in which the patent has been granted.

Nil return.

Q6. Does the institution have any plans on signing up to the Open-COVID pledge (https://opencovidpledge.org/) or any similar initiative that seeks to minimise intellectual property rights barriers during the COVID-19 pandemic? If yes, please specify.

We have not considered signing up to the Open-COVID pledge or otherwise.

Q7. Is the institution considering the licensing of COVID-19 related health technologies to the Covid Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP) during the pandemic? If yes, please specify.

We have not considered the above at this juncture.

If you are unhappy with the way in which your request has been handled and wish to request a review of our response or to make a complaint, please see the attached information sheet and form.

Please do not hesitate to contact me if you have any enquiries regarding this email.

Yours sincerely,
Karen Page

Information Compliance Officer – Freedom of Information
Registrar’s Department

Web: www.nottingham.ac.uk/freedom-of-informat...
Email: [University of Nottingham request email]

show quoted sections